teleconference, page-4

I'll add under your heading, was just about to post a new one:

Just a few points of interest, in my own words, from the call:

1. The phase 2 trial will mainly be funded by the investigator and only cost ACL around $400k

2. This study will help add significant value to the HyAct platform.

3. Clinicians from other conferences are wanting to do additional HA-I studies on other cancers.

4. Funding has been narrowed down and they are pursuing one option they believe will come in the not too distant future. They are very mindful of limited dilution to shareholders. (I don't think we will be tapped at all, maybe a minor raise with someone who wants in on the Oncology - my words)

5. ACL have had a lot of approaches/commercial interest in the HyAct platform, recently.

6. Pete is very happy with current sales of Fonda and it seems it's taking the desired market share at this early stage.

7. Still talking about a $billion company with HyAct and David from Bioshares said, "hopefully you'll be my second favourite billionare", he mentioned he owned ACL shares. Tracey Brown confirmed with David that HyACT has the ability to deliver the drug up to 1000 times more, this got his $billion blood comments out.

8. Pharma are circling around for these types of platforms that simply take a generic and increase efficacy, make the drug a lot cheaper and can open up emerging markets, especially in cancer cases. The pharma patent cliff is fast approaching.


Just a few things.....